Where Jazz Pharmaceuticals’ Defitelio, Vyxeos, and Prialt Stand
Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of $36.2 million in the third quarter—compared to $31.2 million in the third quarter of 2017, which reflected ~17% YoY (year-over-year) growth. Defitelio reported net revenues of $111.7 million during the first nine months of 2018—compared to $97.4 million during the same period in 2017, which reflects ~15% YoY growth.